Investigating a method to reverse lung fibrosis
SOCS domain-mediated fibronectin matrix degradation on fibrosis reversal
['FUNDING_R15'] · NORTHERN ARIZONA UNIVERSITY · NIH-10292074
This study is looking at a new way to help people with idiopathic pulmonary fibrosis (IPF) by using a special protein to break down harmful substances in the lungs that make breathing difficult, with the hope of improving lung function.
Quick facts
| Phase | ['FUNDING_R15'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHERN ARIZONA UNIVERSITY (nih funded) |
| Locations | 1 site (FLAGSTAFF, UNITED STATES) |
| Trial ID | NIH-10292074 on ClinicalTrials.gov |
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF), a serious lung disease with no current effective treatments. The study aims to explore how a specific protein domain, known as the SOCS domain, can help degrade harmful fibronectin matrices produced by myofibroblasts, which contribute to lung fibrosis. By introducing the SOCS domain into lung fibroblasts, researchers hope to reverse the fibrosis process and improve lung function. The approach involves advanced cellular techniques to manipulate and observe the effects of this protein on lung cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are experiencing progressive lung function decline.
Not a fit: Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for reversing lung fibrosis in patients with IPF.
How similar studies have performed: While the approach of targeting fibronectin degradation is innovative, similar strategies in fibrosis research have shown promise, indicating potential for success.
Where this research is happening
FLAGSTAFF, UNITED STATES
- NORTHERN ARIZONA UNIVERSITY — FLAGSTAFF, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: INGRAM, JANI CHERI — NORTHERN ARIZONA UNIVERSITY
- Study coordinator: INGRAM, JANI CHERI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.